4 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 4 |
Follow Eosinophilic Asthma: new trials by email Literature Review of Eosinophilic Asthma trials Research Report on Eosinophilic Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Long-Term Extension Study With Dexpramipexole Dexpramipexole Dihydrochloride - Eosinophilic Asthma | Phase 3 | Terminated | Areteia Therapeutics | 509 | 2024-06-12 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 654 | 2023-03-27 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 1061 | 2023-01-30 | 2025-12-15 |
| Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Reslizumab - Eosinophilic Asthma | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 1052 | 2011-06-01 | 2016-06-06 |
Pulmonary Eosinophilia (4) · Asthma (3)
Eosinophilia (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Hypereosinophilic Syndrome (4) · Leukocyte Disorders (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Bronchial Diseases (3) · Hypersensitivity (3) · Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Lung Diseases, Obstructive (3) · Respiratory Hypersensitivity (3)
Antibodies, Monoclonal, Humanized (1) · reslizumab (1)
Areteia Therapeutics (3) · Teva Branded Pharmaceutical Products R&D, Inc. (1)
Argentina (4) · Brazil (4) · Mexico (4) · South Korea (4) · Ukraine (4) · United States (4) · Japan (3) · Peru (3) · Poland (3) · Romania (3) · South Africa (3) · United Kingdom (3) · Bulgaria (2) · Canada (2) · Chile (2)
Michael E. Wechsler, MD (1) · Sady Alpizar, MD (1) · Salman Siddiqui, MD (1)
2023 (1)